GlassScriptPhysician profile
Heather M Burnside
NPI 1942677307
$3,275.17
in general payments reported to CMS, 2019-2025
27 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $460 · 2023: $871 · 2024: $1,172 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $710.59 | 2021-2025 | Rybelsus, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals LP | $497.74 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $396.06 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $345.70 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $172.75 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $142.13 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $126.04 | 2022-2025 | |
| Astellas Pharma US INC | $119.79 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $116.47 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Exact Sciences Corporation | $110.91 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $100.51 | 2021-2024 | Trintellix |
| Lundbeck LLC | $96.78 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $44.05 | 2021-2022 | |
| Pfizer INC. | $39.12 | 2023-2025 | |
| Axsome Therapeutics, INC. | $27.47 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $26.19 | 2022-2023 | Tirosint, Licart |
| Hologic Sales and Service, LLC | $23.27 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.85 | 2023 | Quviviq |
| Merz North America, INC. | $21.85 | 2022 | |
| Aimmune Therapeutics, INC. | $18.60 | 2024 | |
| Alkermes, INC. | $18.34 | 2024 | Vivitrol |
| Phathom Pharmaceuticals, INC. | $17.85 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $17.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.17 | 2023 | |
| Philips North America LLC | $16.98 | 2022 | |
| Esperion Therapeutics, INC. | $16.49 | 2023 | Nexletol |
| Noven Therapeutics, LLC | $13.10 | 2024 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Burnside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.